We determined the efficacy of the combination of the topical formulation 15% paromomycin sulfate/12% methylbenzethonium chloride (MBCL) and a short course (7 days) of parenteral meglumine antimonate (pentavalent antimony [Sb]) as treatment of American cutaneous leishmaniasis in Colombian patients. Patients were randomly assigned in unequal allocation (2:1:1:1) to group 1 (topical paromomycin/MBCL plus injectable Sb for 7 days), group 2 (topical placebo plus injectable Sb for 7 days), group 3 (topical paromomycin/MBCL plus injectable Sb for 3 days), and group 4 (injectable Sb for 20 days). Cure was defined as complete reepithelialization of all lesions without relapse. Cure rates among groups were as follows: 58% (34 of 59), group 1; 53% (16 of 30), group 2; 20% (6 of 30), group 3; and 84% (26 of 31), group 4. Seventy-one percent of the organisms identified to the species level were Leishmania braziliensis panamensis. We conclude that 10 days of therapy with paromomycin/MBCL does not augment the response of cutaneous leishmaniasis (predominately due to L. braziliensis panamensis) to a short course of treatment with meglumine antimonate.
The study was a randomized, controlled phase 3 trial of showed that the combination of a topical regimen marketed four treatment regimens. Patients were randomly assigned in in Israel for treatment of Old World cutaneous leishmaniaunequal allocation (2:1:1:1) to four groups: group 1 (experisis -paromomycin sulfate/methylbenzethonium chloride mental group), topical paromomycin/MBCL twice a day for (MBCL) -and a short course (7 days) of Sb as treatment of 10 days plus injectable Sb for 7 days; group 2 (first negative New World cutaneous leishmaniasis was 90% curative for control group), topical placebo twice a day for 10 days plus 20 patients. Although concomitant control groups were not injectable Sb for 7 days; group 3 (second negative control involved in that phase 2 trial, we did not think that either group), topical paromomycin/MBCL twice a day for 10 days the topical regimen or the 7-day course of Sb alone would plus injectable Sb for 3 days; and group 4 (positive control have been 90% efficacious. The cure rate among a group group), injectable Sb for 20 days. Since both groups 1 and 2 administered paromomycin/MBCL plus Sb for 3 days was received a topical cream for 10 days in addition to Sb for 7 42%, and that among historical controls administered Sb for days, the study was double-blinded for those two groups. 10 days was 31%.
We report the results of a large, randomized, partially douStudy Population, Inclusion Criteria, and Exclusion Criteria ble-blind, controlled phase 3 trial of the efficacy of the combination of topical paromomycin/MBCL plus injectable meglumThe inclusion and exclusion criteria, parasitological diagnoine antimonate (Sb) for 7 days as treatment of American sis, determination of clinical toxicity, and definitions of recutaneous leishmaniasis.
sponse were identical to those in our previous study [1] . In brief, patients were eligible for the study if they were 18 -60 years old, had cutaneous leishmaniasis proven parasitologically by visualization or culture of organisms, and were otherwise 
Treatment Efficacy Dosage and Administration of Drugs
Of the 150 patients in this study, 82 were cured or apparently Topical formulation. Fifteen percent paromomycin sulfate/ cured (table 1) : 76 patients were initially cured and did not 12% MBCL (Leshcutan) or matching topical placebo was obrelapse during 9 -12 months of follow-up; 4 patients were initained from TEVA Pharmaceutical Industries, Jerusalem. Topitially cured without relapse at the 6-month follow-up; and 2 cal agents were administered as follows. The lesion was cleaned patients (both in group 1) were initially cured but were lost to with soap and water, and then 0.001 mL of formulation per follow-up after 1.5 and 3 months, respectively. 1 mm 2 of lesion was applied by medical personnel twice a day There were 68 treatment failures: treatment failed for 48 for 10 days. Patients were instructed not to rub off the cream.
patients on the basis of ú50% enlargement of a lesion by the Injectable formulation. Meglumine antimonate (Glucanend of treatment or by the 1.5-month follow-up; treatment time) was obtained from Specia, Bogota, Colombia; this agent failed for 9 patients because a lesion had diminished by õ75% was administered intramuscularly at a dosage of 20 mg of at 1.5 months; and treatment failed for 11 patients because an Sb/(kgrd) for 3, 7, or 20 days.
initially healed lesion subsequently enlarged (relapse). The cure rate among group 1 was not different (P Å .82) from that among group 2. The cure rate among group 4 was Ethical Review significantly higher (P õ .025) than that among any of the The study was approved by the Ethical Review Committee other groups. The cure rate among group 3 was significantly of the Universidad Militar Nueva Granada, Bogata.
lower (P õ .02) than that among any of the other groups.
Results Discussion Patient Characteristics
In this phase 3 study of the efficacy of topical paromomycin/ MBCL twice a day for 10 days plus a short course (7 days) Randomization was effective with respect to the mean number of lesions and the mean size of lesions (table 1) . Because of injectable meglumine antimonate as treatment of New World cutaneous leishmaniasis, the cure rate (58%) was no higher of a protocol error, one patient who was randomized to group 1 was instead treated with Sb for 20 days and was analyzed than that of injectable meglumine antimonate alone for 7 days (53%). Because standard treatment with meglumine antimonate as a member of group 4. Before treatment, Leishmania amastigotes were demonstrated by direct examination of Giemsa or for 20 days results in a high rate of cure (Ç90% in our previous study [1] and 84% in this study), it would be difficult to demonmonoclonal antibody -stained smears or biopsy specimens of lesions in all 150 patients. Cultures of 69 of the 150 lesion strate that paromomycin/MBCL improves on the cure rate associated with the standard duration of meglumine antimonate. In biopsy specimens yielded Leishmania. Of the 69 cultured cutaneous syndromes with very different natural histories may Nevertheless, a very high cure rate was associated with paroalso have very different responses to chemotherapy. momycin/MBCL alone in an uncontrolled study [2] in Ecuador, and it is possible that there are Leishmania species for which some regimens of paromomycin/MBCL might improve the ef-
